These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19200910)

  • 1. Telmisartan in high-risk patients intolerant of ACE inhibitors.
    Hall A; Strauss MH
    Lancet; 2009 Feb; 373(9662):458; author reply 459. PubMed ID: 19200910
    [No Abstract]   [Full Text] [Related]  

  • 2. Telmisartan shown to reduce cardiovascular death, myocardial infarction and stroke in ACE-intolerant high-risk patients.
    Cardiovasc J Afr; 2008; 19(5):275. PubMed ID: 18997991
    [No Abstract]   [Full Text] [Related]  

  • 3. Telmisartan in high-risk patients intolerant of ACE inhibitors.
    Link A; Reil JC; Selejan S
    Lancet; 2009 Feb; 373(9662):458; author reply 459. PubMed ID: 19200909
    [No Abstract]   [Full Text] [Related]  

  • 4. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
    Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
    Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Positive added effect of telmisartan. New therapy alternative for a large collection of cardiovascular risk patients].
    MMW Fortschr Med; 2010 Feb; 152(8):48-9. PubMed ID: 20358766
    [No Abstract]   [Full Text] [Related]  

  • 6. Usefulness of RAS inhibition depends on baseline albuminuria.
    Ito S
    Nat Rev Nephrol; 2010 Jan; 6(1):10-1. PubMed ID: 20023682
    [No Abstract]   [Full Text] [Related]  

  • 7. ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.
    Cardiovasc J Afr; 2008; 19(2):108-9; discussion 109-10. PubMed ID: 18516357
    [No Abstract]   [Full Text] [Related]  

  • 8. [What is better here: ACE inhibitor or AT1 blocker?].
    MMW Fortschr Med; 2008 Apr; 150(16):16-7. PubMed ID: 18557213
    [No Abstract]   [Full Text] [Related]  

  • 9. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telmisartan to prevent recurrent stroke: the PRoFESS study: was the baby thrown out with the bathwater?
    McInnes GT
    Stroke; 2009 May; 40(5):1938-40. PubMed ID: 19038906
    [No Abstract]   [Full Text] [Related]  

  • 11. [Erectile dysfunction as a harbinger of cardiovascular events. Long-term vascular protection with telmisartan].
    Arnheim K
    MMW Fortschr Med; 2009 Aug; 151(34-35):62-3. PubMed ID: 19771798
    [No Abstract]   [Full Text] [Related]  

  • 12. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.
    Diener HC
    J Hypertens Suppl; 2009 Jul; 27(5):S31-6. PubMed ID: 19587553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of telmisartan on coronary stenting in patients with acute myocardial infarction compared with enalapril.
    Yokoyama J; Higuma T; Tomita H; Abe N; Oikawa K; Fujiwara T; Yokota T; Yokoyama H; Kimura M; Sasaki S; Hanada H; Osanai T; Okumura K
    Int J Cardiol; 2009 Feb; 132(1):114-20. PubMed ID: 18190989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telmisartan in high-risk patients intolerant of ACE inhibitors.
    Thompson M; Heneghan C; Perera R
    Lancet; 2009 Feb; 373(9662):457-8; author reply 459. PubMed ID: 19200908
    [No Abstract]   [Full Text] [Related]  

  • 17. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
    Serebruany VL; Atar D; Hanley DF
    Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
    [No Abstract]   [Full Text] [Related]  

  • 18. Telmisartan increases adiponectin levels: a meta-analysis and meta-regression of randomized head-to-head trials.
    Takagi H; Umemoto T
    Int J Cardiol; 2012 Mar; 155(3):448-51. PubMed ID: 22192290
    [No Abstract]   [Full Text] [Related]  

  • 19. Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend.
    Van Mieghem W; Billiouw JM; Brohet C; Dupont AG; Gazagnes MD; Heller F; Krzesinski JM; Missault L; Persu A; Piérard L; Rottiers R; Vanhooren G; Vervaet P; Herman AG
    Acta Clin Belg; 2010; 65(2):107-14. PubMed ID: 20491360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan for the reduction of cardiovascular morbidity and mortality.
    Verdecchia P; Angeli F; Gentile G; Mazzotta G; Reboldi G
    Expert Rev Clin Pharmacol; 2011 Mar; 4(2):151-61. PubMed ID: 22115399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.